Tuberous Sclerosis Clinical Trial
— TreatmentOfficial title:
Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy
Verified date | September 2020 |
Source | The University of Texas Health Science Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a multi-center prospective, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of a topically applied formulation of rapamycin to cutaneous angiofibromas in subjects with Tuberous Sclerosis Complex (TSC). Subjects will apply either the topical vehicle containing rapamycin or the topical vehicle alone nightly to their angiofibromas for six months. The primary goal of this study is to evaluate the efficacy of the topical medication for reduction of cutaneous angiofibromas in patients with TSC. The secondary goal of this study is to confirm the safety of the topical medication.
Status | Completed |
Enrollment | 179 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Subjects must be willing and able to comply with all trial requirements. - Subject has a diagnosis of TSC and has visible facial angiofibromas. - Female subjects of child bearing potential must not be pregnant and must agree to use appropriate contraceptive methods . Exclusion Criteria: - Subject is currently receiving therapy with Rapamycin. - Subject is receiving any form of immunosuppression or has previously experienced immune dysfunction. - Subject is currently participating in or has participated within the last 30 days in a clinical trial involving an investigational drug. - Subject has a known hypersensitivity to either the vehicle or Rapamycin. - Subject is a pregnant or nursing female. - Subject has other dermatologic conditions that would preclude or prevent adequate assessment of changes to their facial angiofibromas. - Subject has had laser surgery, cryotherapy, or other dermatologic treatment to their facial angiofibromas within the previous 6 months. |
Country | Name | City | State |
---|---|---|---|
Australia | Sydney Children's Hospital | Sydney | New South Wales |
United States | Kennedy Krieger Institute | Baltimore | Maryland |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Herscot Center for Adults and Children with TSC Massachusetts General Hospital | Boston | Massachusetts |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Texas Scottish Rite Hospital | Dallas | Texas |
United States | The University of Texas Medical School at Houston | Houston | Texas |
United States | UCLA Mattel Children's Hospital | Los Angeles | California |
United States | Jack & Julia Center for TSC at Oakland Children's Hospital & Research Center | Oakland | California |
United States | Clinic Without Walls | Saint Paul | Minnesota |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston |
United States, Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of Events of Dermatologic Sensitivity at the Site of Application | Dermatologic sensitivity includes pain, pruritis, or erythema at the application site. | 6 months | |
Other | Number of Participants With Systemic Uptake of Topically Applied Rapamycin | Blood levels checked to confirm the lack of systemic rapamycin. | 6 months | |
Primary | Change From Baseline in the Facial Angiofibroma Grading Scale (AGS) Score | Subject's lesion/s will be digitally photographed before initial application (visit 1), at each study visit (visits 2 through 6), and immediately prior to study termination (visit 7). Following completion of the study, all photographs will be evaluated by two independent dermatologists blinded to both the treatment arm and the stage of treatment. The dermatologists will assess each photograph's appearance using the facial Angiofibroma Grading Scale (AGS), which assesses the forehead, nose, cheeks, and chin for erythema, average lesion size, lesion density, and percent involvement, as well as presence of any pedunculated angiofibromas. A total score is reported with a range of 0 to 202, with higher scores representing a worse outcome. | baseline, 6 months | |
Secondary | Photo Readers' Rating (Better, Same, or Worse) of Paired Baseline and End-of-trial (EOT) Photographs for Each Patient | baseline, 6 months | ||
Secondary | Change in Quality of Life (QOL) Questionnaire Scores as Assessed by the Dermatology Life Quality Index (DLQI) | The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. It is designed for people aged 16 years and above. Each question is scored from 0 to 3, giving a possible total score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). | baseline, 6 months | |
Secondary | Change in Quality of Life (QOL) Questionnaire Scores as Assessed by the Children's Dermatology Life Quality Index (CDLQI) | The Children's Dermatology life Quality Index (DLQI) is validated from the age of four years to 16 years. It is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible total score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). | baseline, 6 months | |
Secondary | Change in Quality of Life (QOL) Questionnaire Scores as Assessed by the Family Dermatology Life Quality Index (FDLQI) | The Family Dermatology life Quality Index (FLQI) is designed for adult (more than 16 years of age) family members or partners of patients (of any age) with any skin disease. It is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible total score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). | baseline, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT00552955 -
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|
||
Recruiting |
NCT03422367 -
JASPER Early Intervention for Tuberous Sclerosis
|
N/A | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Unknown status |
NCT00490789 -
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
|
Phase 2 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT02104011 -
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
|
Phase 2 | |
Recruiting |
NCT02461459 -
Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
|
||
Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
Terminated |
NCT01092208 -
Studies of Autistic Patients: Gene Networks and Clinical Subtypes
|
||
Active, not recruiting |
NCT01954693 -
A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
|
Phase 2 | |
Completed |
NCT03826628 -
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
Completed |
NCT00989742 -
Doxycycline In Lymphangioleiomyomatosis (LAM)
|
Phase 4 | |
Recruiting |
NCT05286632 -
KidneYou - Innovative Digital Therapy
|
N/A | |
Withdrawn |
NCT04344626 -
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
|
N/A | |
Recruiting |
NCT05199402 -
Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
|
||
Recruiting |
NCT00001975 -
Study of Skin Tumors in Tuberous Sclerosis
|